Opko Health, Inc.
OPK- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000944809
In the last 90 days, Opko Health, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $303.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:09 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Revenue | $606.9M | $713.1M | $863.5M | $1.00B | $1.77B |
| Cost of revenue | $400.9M | $494.6M | – | – | – |
| Gross profit | $205.9M | $218.5M | – | – | – |
| Operating expenses | – | – | $1.02B | $1.23B | $1.76B |
| Research and development | $124.0M | $105.2M | $89.6M | $73.9M | $76.8M |
| Selling, general and administrative | $223.0M | $304.2M | $300.6M | $372.7M | $468.9M |
| Operating income | -$117.4M | -$152.1M | -$157.0M | -$226.3M | $18.8M |
| Interest expense | $0 | – | $13.5M | – | – |
| Income tax | -$15.7M | $42.8M | $4.44M | -$63.5M | $15.5M |
| Net income | -$225.7M | -$53.2M | -$188.9M | -$328.4M | -$30.1M |
| EPS, basic | $-0.30 | $-0.08 | $-0.25 | $-0.46 | $-0.05 |
| EPS, diluted | $-0.30 | – | – | $-0.46 | $-0.05 |
| Weighted shares, basic | 751.1M | 694.0M | 751.8M | 719.1M | 648.1M |
| Weighted shares, diluted | 751.1M | – | – | 719.1M | 648.1M |
| Margins and growth | |||||
| Gross margin | 33.9% | 30.6% | – | – | – |
| Operating margin | -19.3% | -21.3% | -18.2% | -22.5% | 1.1% |
| Net margin | -37.2% | -7.5% | -21.9% | -32.7% | -1.7% |
| Revenue growth, year over year | −14.9% | −17.4% | −14.0% | −43.4% | +23.6% |
| Net income growth, year over year | – | – | – | – | −198.6% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Cash and equivalents | $364.4M | $426.6M | $95.9M | $153.2M | $134.7M |
| Accounts receivable | $90.3M | $118.0M | $123.4M | $127.3M | $259.6M |
| Inventory | $65.8M | $56.8M | $65.7M | $74.1M | $86.5M |
| Total current assets | $581.9M | $662.1M | $309.5M | $394.5M | $823.0M |
| Property, plant and equipment | $73.9M | $70.1M | $75.4M | – | – |
| Goodwill | $484.3M | $529.3M | $598.3M | $595.9M | $520.6M |
| Intangible assets | $516.3M | $616.6M | $740.3M | $823.5M | $321.7M |
| Total assets | $1.93B | $2.20B | $2.01B | $2.17B | $2.40B |
| Accounts payable | $41.1M | $47.1M | $69.7M | $67.0M | $82.0M |
| Short-term debt | $344.0M | $1.38M | $1.99M | – | – |
| Total current liabilities | $146.7M | $193.1M | $200.1M | $213.5M | $330.0M |
| Long-term debt | $2.26M | $3.00M | $7.73M | $256.3M | $205.3M |
| Total liabilities | $664.0M | $834.8M | $622.5M | $605.6M | $714.6M |
| Shareholders' equity | $1.27B | $1.37B | $1.39B | $1.56B | $1.69B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Feb 27, 2024 | Feb 23, 2023 | Feb 24, 2022 |
| Operating cash flow | -$178.5M | -$183.5M | -$28.2M | -$95.2M | $38.3M |
| Capital expenditures | $12.3M | $25.0M | $16.3M | $24.6M | $32.2M |
| Free cash flow | -$190.8M | -$208.5M | -$44.5M | -$119.8M | $6.18M |
| Depreciation and amortization | $91.6M | $98.2M | $105.3M | $108.7M | $78.7M |
| Stock-based compensation | $10.7M | $11.0M | $11.4M | $18.5M | $13.6M |
| Share buybacks | $47.0M | $90.2M | – | – | – |
| Investing cash flow | $230.3M | $352.2M | -$18.2M | $91.0M | $35.9M |
| Financing cash flow | -$118.1M | $184.2M | -$11.3M | $23.0M | -$10.4M |
| Net change in cash | -$62.9M | $349.7M | -$57.3M | $18.5M | $62.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.8% | 1.5% | 1.3% | 1.8% | 0.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 20, 2026 | 742.5M | −3.3% | SEC |
| Jul 17, 2026 | 746.3M | −6.0% | SEC |
| Apr 17, 2026 | 755.1M | −4.8% | SEC |
| Jan 30, 2026 | 759.1M | +13.0% | SEC |
| Oct 17, 2025 | 767.7M | +12.5% | SEC |
| Jul 21, 2025 | 793.8M | +13.8% | SEC |
| Apr 15, 2025 | 793.1M | +13.8% | SEC |
| Jan 31, 2025 | 671.6M | −3.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.